Equities

TrivarX Ltd

TrivarX Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.028
  • Today's Change-0.001 / -3.45%
  • Shares traded211.26k
  • 1 Year change-6.67%
  • Beta1.1467
Data delayed at least 20 minutes, as of Jun 07 2024 07:10 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

TrivarX Limited, formerly Medibio Limited, is an Australia-based mental health technology company engaged in the use of objective measures to aid in the early detection and screening of mental health conditions. Through the Company’s corporate health product, it offers mental well-being solutions for businesses and is also developing products to serve the healthcare provider market. The principal activity of the Company is conducting clinical research, product development and early-stage commercialization of a mental health technology using objective biomarkers to assist in the screening, diagnosing, monitoring, and management of depression and other mental health conditions. It has launched its consumer mobile application to help measure, monitor, and manage stress, called LUCA. LUCA is a biometric assessment tool that measures sleep stress, activity stress, and cardiac stress that allows consumers to monitor their daily stress levels through their own personal wearable device.

  • Revenue in AUD (TTM)20.81k
  • Net income in AUD-3.74m
  • Incorporated1987
  • Employees4.00
  • Location
    TrivarX LtdLevel 4, 100 Albert RoadSOUTH MELBOURNE 3205AustraliaAUS
  • Phone+61 86189-1155
  • Fax+61 39077-9233
  • Websitehttps://medibio.com.au/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Anatara Lifesciences Ltd0.00-1.75m8.41m----5.83-----0.014-0.0140.000.00760.00-------103.15-59.64-115.72-66.52-------1,927.05----0.00------20.10---40.49--
Avecho Biotechnology Ltd473.55k-3.44m9.51m29.00--1.49--20.08-0.0016-0.00160.00020.0020.08882.070.5132---64.45-47.08-75.73-55.25-9.2578.67-725.70-156.438.19--0.0267---58.07-19.42-46.71------
Bioxyne Ltd8.65m-14.17m10.23m16.00--3.28--1.18-0.0074-0.00740.00440.00151.836.1210.50---302.23-22.07-418.10-28.5038.3045.13-165.04-39.691.50--0.00--1,013.0520.97-292.69---19.86--
Althea Group Holdings Ltd28.70m-20.99m10.54m----0.6874--0.3672-0.059-0.0590.07960.03780.61812.475.53---45.22-31.09-66.73-36.3254.6450.76-73.15-101.390.4899-46.550.2756--22.43335.18-13.21------
Firebrick Pharma Ltd0.00-4.57m10.94m----6.27-----0.0266-0.02660.000.00890.00-------120.70---136.04----------4.37--0.00---79.85---79.18------
TrivarX Ltd20.81k-3.74m11.88m4.00--1.17--570.87-0.0182-0.01820.000090.02490.0023-------42.02-41.56-47.15-50.51100.0092.74-17,949.78-334.16---147.210.0072---4.69-18.0675.85------
Nyrada Inc3.08m-4.98m12.92m----2.45--4.19-0.0319-0.03190.01980.02940.3983-------64.37-64.90-71.93-84.66-----161.62-380.62---15,086.390.00--42.54229.09-96.52------
Tissue Repair Ltd457.52k-3.28m13.30m----0.7724--29.07-0.0542-0.05420.00760.28480.0209--7.95---14.96---15.46--98.19---716.30--25.84--0.00------38.95------
Chimeric Therapeutics Ltd0.00-11.31m13.80m----0.8377-----0.027-0.0270.000.01910.00-------45.96---69.36-------------10.010.1596-------60.40------
Radiopharm Theranostics Ltd0.00-46.82m13.81m----0.4601-----0.1343-0.13430.000.06520.00-------63.11---77.85-------------7.480.00-------13.78------
Patrys Ltd1.70m-5.12m14.40m15.00--2.87--8.50-0.0025-0.00250.00080.00240.1978--0.5828---59.77-43.96-68.99-47.06-----302.26-230.44----0.00---14.4540.52-4.15------
Argent BioPharma Ltd1.32m-17.02m14.49m----8.61--10.94-3.32-3.320.10030.03720.08130.70781.58---105.32-111.29-345.98-171.0521.8732.52-1,295.20-632.420.6561-24.850.4104---28.4147.31-2.34---16.20--
BTC Health Ltd16.03k-8.26m14.91m1.00--2.759.03930.11-0.0305-0.03050.000050.01670.0017--0.031---89.67-23.15-91.36-24.64-----51,522.02-2,498.18---0.07870.00---86.04-26.76-1,665.01------
Medlab Clinical Ltd366.64k-3.94m15.07m14.00------41.11-1.73-1.730.1606-0.30680.1069--5.82---103.72-55.07-240.52-69.7584.7752.86-970.74-335.43---342.19-----28.90-29.8318.55---30.00--
Calmer Co International Ltd2.46m-4.50m15.09m--------6.13-0.0083-0.00830.0039-0.00050.6551.349.62---119.81-139.15-231.33-198.5536.0330.26-182.94-388.810.482-9.361.22---13.00239.4311.40------
Lumos Diagnostics Holdings Ltd12.36m-13.27m15.88m----1.14--1.29-0.0357-0.03570.03510.02880.34182.246.37---36.70-40.15-55.14-56.6759.7345.97-107.38-162.900.479-6.250.4803---9.4239.2980.38---38.50--
Data as of Jun 07 2024. Currency figures normalised to TrivarX Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

9.69%Per cent of shares held by top holders
HolderShares% Held
FIL Investment Management (Hong Kong) Ltd.as of 30 Apr 202432.81m9.69%
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.